New pill aims to tame chronic hepatitis b

NCT ID NCT05960240

Completed Disease control Sponsor: Arbutus Biopharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests AB-101, an oral drug that blocks a protein called PD-L1 to help the immune system fight the hepatitis B virus. The study involves 128 people, including healthy volunteers and patients with chronic hepatitis B. Researchers are primarily checking for safety and how the body processes the drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB-101 (an oral PD-L1 inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for chronic hepatitis B, potentially reducing the need for lifelong medication.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The drug may cause immune-related side effects and may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

ASST Papa Giovanni XXIII -Osepedale

Bergamo, Italy
Clinial Republican Hospital "Timofei Mosneaga"

Chisinau, Moldova
Clinical Republican Hospital "Timofei Mosneaga", ARENSIA E. M.

Bucharest, Romania
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

Milan, Italy
Municipal Non-Profit Enterprise Kyiv City Clinical Hospital No12 Executive Body of Kyiv City Council

Kyiv, Ukraine
National University Hospital

Singapore, Singapore
New Zealand Clinical Research Auckland

Grafton, Auckland, New Zealand
Prince of Wales Hospital

Hong Kong, Hong Kong, Hong Kong
Queen Mary Hospital - PPDS

Hong Kong, Hong Kong, Hong Kong
Singapore General Hospital

Singapore, Singapore

More trials for these conditions

Other studies related to the condition(s) this trial covers.